Ardea's Phase III Program For Promising Gout Drug Begins To Take Shape

Positive efficacy and clean-as-whistle topline results for unpartnered RDEA594 leave some analysts predicting the drug could become a front-runner in the gout field.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet